1. Bicker, O., Ziegler, B. E., Hebold, G.: 2-[2-cyanaziridinyl-(1)-]-2-[-2-carbamocyl aziridinyl-(1)]-propane BM 12 531. A new substance with immune stimulating action. I.R.C.S. Med. Sci. 5, 299 (1977).
2. Bicker, U., Hebold, G., Ziegler, A. E., Maus, W.: Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamocyl aziridinyl-(1)-]-propane BM 12 531. (in press) (1978).
3. Bonadonna, G., Mathé, G., Salmon, S. E. (eds.): Adjuvant therapies and markers of post-surgical minimal residual disease I. Berlin, Heidelberg, New York: Springer 1979.
4. Bruley-Rosset, M., Florentin, I., Kiger, N., Goldstein, A., Mathé, G.: Prevention of aged-induced immunodepression in mice by chronic treatment with thymosin and systemic adjuvants of immunity. Cancer Immunol. Immunother. (in press) (1978).
5. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666 (1975).